{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Relevance of Sitagliptin in Indian type 2 diabetes patients with Ease of administration & Durable Control

  1. Which of the following are characteristics associated with diabetics in India? *

  2. At which Body Mass Index values Indians should be screened for diabetes? *

  3. Lower adherence rate with antidiabetics agents is due to- *

  4. What are the unmet needs or challenges with current drugs like metformin, SU, TZD etc? *

  5. Do you agree that gliptins have better treatment adherence than conventional alternatives like SU or TZD? *

  6. In your opinion, percentage of DPP4 inhibition in 24 hours or selectivity of inhibition can affect efficacy of different gliptins? *

  7. Can gliptins be considered as monotherapy in patients who are intolerant of or have contraindications to metformin, such as patients with chronic kidney disease? *

  8. Do you agree that gliptins be considered for those who are at high risk for hypoglycemia (those using SU/Insulins or elderly)? *

  9. Gliptins be considered as add-on drug therapy for patients- *

  10. In terms of clinical trial data for Cardiovascular safety, which gliptin is better? *

  11. Which gliptin do you prefer in renal compromised patients? *

  12. Which gliptin do you prefer in hepatic compromised patients? *

  13. Which antidiabetic drug do you prefer if eGFR is below 30ml/min? *

  14. Which of the following gliptins has extra glycemic benefits? *

  15. As shown in UKPDS and DCCT studies, HbA1c reduction delays the diabetes complication. Can 0.8% reduction by sitagliptin help in delaying the complication? *

  16. In your clinical experience, which gliptin offers 24-hr better circadian glucose control? *

  17. Can gliptins be considered for those who are having weight gain as a side effect of antidiabetic treatment? *

  18. In your clinical experience on average how much is the reduction in Hb1c with sitagliptin monotherapy? *

  19. What is your preferred dose of sitagliptin in CKD patient with eGFR 30-45 ml/min? *

  20. Which DPP4i does not have a dedicated CVOT trial and proven CV safety? *

  21. What is your preferred approach for therapy initiation in newly diagnosed T2DM? *
  22. How often do you observe hypoglycaemia and what is your choice of therapy in patients with history of hypoglycaemia? *